[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545288":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":46,"locations":52,"responsibleParty":71,"collaborators":11,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":11,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":11,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":11,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Modern Biosciences Ltd","INDUSTRY",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Itraconazole 200mg","ACTIVE_COMPARATOR",null,[13,14],"Drug: leramistat 40mg","Drug: Itraconazole 200 mg",{"label":16,"type":10,"description":11,"interventionNames":17},"Part 2: Phenytoin 100mg",[13,18],"Drug: Phenytoin 100 Mg Oral Capsule",{"label":20,"type":10,"description":11,"interventionNames":21},"Part 3: Simvastatin 40mg",[13,22],"Drug: Simvastatin 40mg",{"label":24,"type":10,"description":11,"interventionNames":25},"Part 4: Upadacitinib 15 mg",[13,26],"Drug: Upadacitinib 15 MG",[28,33,36,39,42],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","leramistat 40mg","Oral capsule",[9,16,20,24],{"type":29,"name":34,"description":31,"armGroupLabels":35,"otherNames":11},"Itraconazole 200 mg",[9],{"type":29,"name":37,"description":31,"armGroupLabels":38,"otherNames":11},"Phenytoin 100 Mg Oral Capsule",[16],{"type":29,"name":40,"description":31,"armGroupLabels":41,"otherNames":11},"Simvastatin 40mg",[20],{"type":29,"name":43,"description":44,"armGroupLabels":45,"otherNames":11},"Upadacitinib 15 MG","Oral Capsule",[24],[47],{"name":48,"role":49,"phone":50,"phoneExt":11,"email":51},"Study Team","CONTACT","+44 (0)207 444 0066","ist05@istesso.co.uk",[53],{"facility":54,"status":55,"city":56,"state":11,"zip":11,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Celerion","RECRUITING","Belfast","United Kingdom","UK",{"type":60,"coordinates":61},"Point",[62,63],-5.92541,54.59682,{"lat":63,"lon":62},[66,68],{"name":67,"role":49,"phone":11,"phoneExt":11,"email":11},"Phase 1 Unit",{"name":69,"role":70,"phone":11,"phoneExt":11,"email":11},"Nadine Abdullah","PRINCIPAL_INVESTIGATOR",{"type":72,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100545288","phase-1-drug-drug-interaction-ddi-study-of-leramistat-in-healthy-adult-subjects-100545288",false,"NCT06379958","Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects","A Phase 1, Open-label, 4-Part, Drug-Drug Interaction Study to Evaluate the Effects of Inhibition and Induction of CYP3A4 on the Pharmacokinetics of Leramistat, to Assess the Effect of Leramistat on the Pharmacokinetics of Simvastatin, and to Evaluate the Pharmacokinetic Interaction Between Leramistat and Upadacitinib (RINVOQ®) in Healthy Adult Subjects","Principal Inclusion Criteria:\n\nHealthy, adult, male or female of non childbearing potential 18 to 55 years of age.\n\nPrincipal Exclusion Criteria:\n\nHistory or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.\n\nHistory of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.",true,"ALL","18 Years","55 Years",{"count":85,"type":86},48,"ESTIMATED","INTERVENTIONAL",[89],"PHASE1","A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.",[92],"Pharmacokinetics","2024-08-08",{"date":95,"type":96},"2024-08-09","ACTUAL",{"date":98,"type":96},"2024-04-08",{"date":100,"type":86},"2024-09-30",{"name":5,"class":6},1]